Probiotic effects of orally administered <i>Lactobacillus reuteri</i>‐containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial

Iniesta, Margarita; Herrera, David; Montero, Eduardo; Zurbriggen, Milena Mercedes; Matos, Ana Rita Fernández; Marín, María J.; Sánchez, María Carmen; Llama-Palacio, Arancha; Sanz, Mariano

doi:10.1111/j.1600-051x.2012.01914.x

Cited by 153 publications

(213 citation statements)

References 23 publications

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the suppression of inflammatory cytokine production in gingival tissue by gastric administration of LG2055 may correlate with β-defensin production in oral sites. Since the administration of tablets containing Lactobacillus reuteri significantly decreased the number of periodontal pathogens in the subgingival microbiota and was effective as an adjunct to scaling and root planing in chronic periodontitis in a randomized clinical trial 35, 36 , it is probable that the results observed in our animal experiment will also be seen in the human oral cavity in clinical trials. Further study is required regarding the detailed mechanism underlying the induction of β-defensin production in the oral cavity by gastric administration of LG2055.…”

Section: Discussionmentioning

confidence: 94%

Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease

Kobayashi

Sakai

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Probiotics have been used to treat gastrointestinal disorders. However, the effect of orally intubated probiotics on oral disease remains unclear. We assessed the potential of oral administration of Lactobacillus gasseri SBT2055 (LG2055) for Porphyromonas gingivalis infection. LG2055 treatment significantly reduced alveolar bone loss, detachment and disorganization of the periodontal ligament, and bacterial colonization by subsequent P. gingivalis challenge. Furthermore, the expression and secretion of TNF-α and IL-6 in gingival tissue was significantly decreased in LG2055-administered mice after bacterial infection. Conversely, mouse β-defensin-14 (mBD-14) mRNA and its peptide products were significantly increased in distant mucosal components as well as the intestinal tract to which LG2055 was introduced. Moreover, IL-1β and TNF-α production from THP-1 monocytes stimulated with P. gingivalis antigen was significantly reduced by the addition of human β-defensin-3. These results suggest that gastrically administered LG2055 can enhance immunoregulation followed by periodontitis prevention in oral mucosa via the gut immune system; i.e., the possibility of homing in innate immunity.

show abstract

Section: Discussionmentioning

confidence: 94%

Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease

Kobayashi

Sakai

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Several in vitro studies (Teughels et al, 2007; van Essche et al, 2012) and recent clinical studies (Iniesta et al, 2012; Teughels et al, 2013; Yanine et al, 2013) have suggested that these allegedly beneficial bacteria can cause antagonism toward Gram-negative bacteria.…”

Section: Discussionmentioning

confidence: 99%

Effect of an oxygenating agent on oral bacteria in vitro and on dental plaque composition in healthy young adults

Mostajo

Reijden

Buijs

et al. 2014

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Oral bacteria live in symbiosis with the host. Therefore, when mouthwashes are indicated, selective inhibition of taxa contributing to disease is preferred instead of broad-spectrum antimicrobials. The potential selectivity of an oxygenating mouthwash, Ardox-X® (AX), has not been assessed. The aim of this study was to determine the antimicrobial potential of AX and the effects of a twice-daily oral rinse on dental plaque composition.Material and methods: In vitro, 16 oral bacterial strains were tested using agar diffusion susceptibility, minimum inhibitory and minimum bactericidal concentration tests. A pilot clinical study was performed with 25 healthy volunteers. Clinical assessments and microbiological sampling of supragingival plaque were performed at 1 month before the experiment (Pre-exp), at the start of the experiment (Baseline) and after the one-week experimental period (Post-exp). During the experiment individuals used AX mouthwash twice daily in absence of other oral hygiene measures. The microbiological composition of plaque was assessed by 16S rRNA gene amplicon sequencing.Results: AX showed high inter-species variation in microbial growth inhibition. The tested Prevotella strains and Fusobacterium nucleatum showed the highest sensitivity, while streptococci and Lactobacillus acidophilus were most resistant to AX. Plaque scores at Pre-exp and Baseline visits did not differ significantly (p = 0.193), nor did the microbial composition of plaque. During a period of 7-days non-brushing but twice daily rinsing plaque scores increased from 2.21 (0.31) at Baseline to 2.43 (0.39) Post-exp. A significant microbial shift in composition was observed: genus Streptococcus and Veillonella increased while Corynebacterium, Haemophilus, Leptotrichia, Cardiobacterium and Capnocytophaga decreased (p ≤ 0.001).Conclusion: AX has the potential for selective inhibition of oral bacteria. The shift in oral microbiome after 1 week of rinsing deserves further research.

show abstract

“…Aside from its previously described positive contributions in the heath of oral (Iniesta et al, 2012; Martin-Cabezas et al, 2016) and gastrointestinal (GI) tract mucosa (Cruchet et al, 2015; Gao et al, 2015; Liu et al, 2012; Schreiber et al, 2009; Varian et al, 2016a; Walter et al, 2011), the probiotic has systemic effects on the immune and hormonal profile of the host animal (Buffington et al, 2016; Erdman and Poutahidis, 2014; Ibrahim et al, 2014; Lakritz et al, 2014; Lee et al, 2016; Levkovich et al, 2013; Livingston et al, 2010; Poutahidis et al, 2013a,b, 2014, 2015; Simon et al, 2015; Varian et al, 2016a,b, 2014). Mice that consume L. reuteri live longer (Ibrahim et al, 2014; Varian et al, 2016a) and resist obesity (Fak and Backhed, 2012; Poutahidis et al, 2013b; Qiao et al, 2015; Varian et al, 2016b, 2014) and age-associated atrophic changes of skeletal muscle (Varian et al, 2016a), testis (Poutahidis et al, 2014), and thyroid (Varian et al, 2014) and thymus glands (Varian et al, 2016a).…”

Section: Introductionmentioning

confidence: 99%

Microbial lysate upregulates host oxytocin

Varian

Poutahidis

DiBenedictis

et al. 2017

Brain, Behavior, and Immunity

120

View full text Add to dashboard Cite

Neuropeptide hormone oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health. It was previously shown that feeding of a human commensal microbe Lactobacillus reuteri (L. reuteri) is sufficient to up-regulate endogenous oxytocin levels and improve wound healing capacity in mice. Here we show that oral L. reuteri-induced skin wound repair benefits extend to human subjects. Further, dietary supplementation with a sterile lysate of this microbe alone is sufficient to boost systemic oxytocin levels and improve wound repair capacity. Oxytocin-producing cells were found to be increased in the caudal paraventricular nucleus [PVN] of the hypothalamus after feeding of a sterile lysed preparation of L. reuteri, coincident with lowered blood levels of stress hormone corticosterone and more rapid epidermal closure, in mouse models. We conclude that microbe viability is not essential for regulating host oxytocin levels. The results suggest that a peptide or metabolite produced by bacteria may modulate host oxytocin secretion for potential public or personalized health goals.

show abstract

Probiotic effects of orally administered Lactobacillus reuteri‐containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial

Abstract: The effect of L. reuteri administered in tablets resulted in a reduction in the number of selected periodontal pathogens in the subgingival microbiota, without an associated clinical impact.

Cited by 153 publications

References 23 publications

Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease

Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease

Effect of an oxygenating agent on oral bacteria in vitro and on dental plaque composition in healthy young adults

Microbial lysate upregulates host oxytocin

Contact Info

Product

Resources

About